Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
1.980
-0.020 (-1.00%)
At close: Apr 10, 2026, 4:00 PM EDT
1.950
-0.030 (-1.52%)
Pre-market: Apr 13, 2026, 6:03 AM EDT
Serina Therapeutics Revenue
In the year 2025, Serina Therapeutics had annual revenue of $130.00K with 132.14% growth.
Revenue (ttm)
$130.00K
Revenue Growth
+132.14%
P/S Ratio
187.55
Revenue / Employee
$10,000
Employees
13
Market Cap
24.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 130.00K | 74.00K | 132.14% |
| Dec 31, 2024 | 56.00K | -3.10M | -98.22% |
| Dec 31, 2023 | 3.15M | 3.12M | 9,173.53% |
| Dec 31, 2022 | 34.00K | -110.00K | -76.39% |
| Dec 31, 2021 | 144.00K | -217.00K | -60.11% |
| Dec 31, 2020 | 361.00K | -1.37M | -79.11% |
| Dec 31, 2019 | 1.73M | 332.00K | 23.78% |
| Dec 31, 2018 | 1.40M | -8.00K | -0.57% |
| Dec 31, 2017 | 1.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Barinthus Biotherapeutics | 14.97M |
| Daré Bioscience | 1.03M |
| Lexaria Bioscience | 522.00K |
| Exicure | 500.00K |
| Outlook Therapeutics | 205.70K |
SER News
- 6 days ago - Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit - GlobeNewsWire
- 10 days ago - Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan - GlobeNewsWire
- 20 days ago - Serina Therapeutics to Present at the 38th Annual Roth Conference - GlobeNewsWire
- 25 days ago - Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 6 weeks ago - Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 7 weeks ago - Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 2 months ago - Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event - GlobeNewsWire
- 2 months ago - Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease - GlobeNewsWire